Navigation Links
Jazz Pharmaceuticals, Inc. Announces LUVOX CR Launch Plans and Reports Development Pipeline Progress at Investor Day Presentation
Date:3/13/2008

- Product Sales of $90 Million to $120 Million Expected in 2008 - Initial Results from JZP-6 Phase III Clinical Trial Expected by Year End - New Data Provided on Pipeline and Early-Stage Development Portfolio

- 2008 Financial Guidance Provided

PALO ALTO, Calif., March 13 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today provided a comprehensive update on its commercial activities and near-term product development pipeline, and provided 2008 financial guidance, for investors and analysts at its Investor Day meeting in New York City.

"Jazz Pharmaceuticals' strategy combines a strong commercial presence with a rapidly advancing product development pipeline addressing important patient needs in neurological and psychiatric disorders," said Samuel R. Saks, M.D., Chief Executive Officer. "With the anticipated launch of LUVOX CR later this month, continued strong performance from our XYREM sales efforts, top-line results from our first Phase III clinical study of JZP-6 for fibromyalgia syndrome and progress across our R&D portfolio, 2008 is positioned to be a transformational year for Jazz Pharmaceuticals."

Commercial Updates

Jazz Pharmaceuticals expects to launch once daily LUVOX(R) CR (fluvoxamine maleate) Extended-Release Capsules with shipments to wholesalers by the end of March. The product was approved by the U.S. Food and Drug Administration (FDA) on February 28, 2008 for the treatment of obsessive compulsive disorder (OCD) and social anxiety disorder (SAD). LUVOX CR will be priced to wholesalers at $3.25 per capsule for 100 mg and 150 mg strengths. Ex-factory sales of LUVOX CR are expected to be in the range of $40 million to $60 million during 2008.


'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
2. Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
3. Renhuang Pharmaceuticals, Inc. Retains CCG Elite
4. Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies
5. Jazz Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 13, 2008
6. NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers
7. Jazz Pharmaceuticals, Inc. Announces Submission of Complete Response to FDA Approvable Letter for LUVOX(R) CR
8. Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR
9. Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director
10. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
11. American Stock Exchange LLC to Delist Securities of Samaritan Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... together advocates from cardiologists to coaches, NATICK, ... BSX ) today announced the public debut of ... aimed at addressing disparities,in cardiovascular care for the ... Americans. The Company said it is collaborating,on the ...
... New Dress, Casual and Athletic Lines Now Available in Retail Outlets ... ... all day,it,s no wonder feet are subject to more injury than any other ... will have,painful foot problems at some time in their lives. But that is ...
... PITTSBURGH, Feb. 4 The sponsors of two of,Pittsburgh,s ... the,Pennsylvania Attorney General,s Office of approval of their intention ... As of,February 1, 2008, the Sisters of the Holy ... Manor Corporation, a 186 bed not,for profit long term ...
... Univision,s two-day radiothon event on Feb. 7 and 8, ... contribute, to St. Jude Children,s Research Hospital,s mission ... cancer and other catastrophic ... Radio, a division of,Univision Communications Inc. and the leading ...
... be Webcast -, CHICAGO, Feb. 4 ... a biopharmaceutical company engaged in the,discovery, development and ... infection, cancer and respiratory diseases, today,announced that its ... in,the "Antibiotics: Super Drugs Against Super Bugs" panel ...
... The Juvenile Diabetes Research Foundation (JDRF), the worlds ... announced today that it is partnering with Plureon ... that focuses on developing therapeutic applications of stem ... Development Partnership Program, JDRF is providing $500,000 over ...
Cached Medicine News:Health News:Boston Scientific Launches Educational Initiative to Address Disparities in Cardiovascular Care 2Health News:Boston Scientific Launches Educational Initiative to Address Disparities in Cardiovascular Care 3Health News:Boston Scientific Launches Educational Initiative to Address Disparities in Cardiovascular Care 4Health News:New Fashion-Forward Footwear from Aetrex Offers Patented Customization to Help Eliminate Foot Pain 2Health News:New Fashion-Forward Footwear from Aetrex Offers Patented Customization to Help Eliminate Foot Pain 3Health News:Pennsylvania Attorney General Approves Vincentian Collaborative System-Marian Manor Integration 2Health News:Hispanic Radio Listeners Nationwide to Support Life-Saving Efforts Against Childhood Cancer 2Health News:Advanced Life Sciences to Participate in Antibiotics Expert Panel at the 10th Annual BIO CEO & Investor Conference 2Health News:JDRF partners with Plureon to explore generating insulin-producing cells from adult stem cells 2
(Date:1/15/2014)... 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument ... . (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) ... upgrade and policy support, China,s ... over the years, with total market size rising ... billion yuan in 2012. Trauma products, ...
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ... the "Dental Consumables Market - Global Industry ... - 2018" report to their offering. ... ) Dental consumables are products which are ... impairments, for tooth restoration and in treatment of ...
(Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation ... to support older adults suffering from the severe ... AARP and its members are committed to helping those ... AARP and AARP Foundation will match dollar-for-dollar contributions up ... aid. The matching program will be administered through AARP ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3
... PHILADELPHIA, July 28 Shire plc (LSE: SHP,NASDAQ: ... it has received a Complete Response letter today for INTUNIV(TM),(guanfacine) ... comes following labeling discussions with the FDA that did not,result ... The FDA did not identify safety ...
... , ... , Oldsmar, Fla., July 27 Cryo-Cell ... and most established leaders in stem cell innovation today announced ... a Brazilian-based global regenerative technology leader and stem cell research ...
Cached Medicine Technology:FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents 2FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents 3FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents 4FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents 5FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents 6Cryo-Cell Announces C'elle(SM) Research and Development Collaboration with Cryopraxis Cryobiology Ltd. 2Cryo-Cell Announces C'elle(SM) Research and Development Collaboration with Cryopraxis Cryobiology Ltd. 3Cryo-Cell Announces C'elle(SM) Research and Development Collaboration with Cryopraxis Cryobiology Ltd. 4Cryo-Cell Announces C'elle(SM) Research and Development Collaboration with Cryopraxis Cryobiology Ltd. 5
The ideal on-the-spot reference for residents and practitioners seeking fast facts on fracture management....
Pocket Sports Medicine is the result of a collaboration between outstanding Editors and Contributors. The program covers the field so that both specialists and general orthopedists will find expert g...
Bones is a remarkable guide for the Medical Student, Nurse, Nurse Practitioner, Physician's Assistant or Physician to Bones....
The Urinary System Flash Cards product uses the time tested content and images from BryanEdwards.com and displays the necessary images to demonstrate the urinary system....
Medicine Products: